Kurume University

Green Peptide Co., Ltd.

Mamoru Harada

Kyogo Itoh

Ryuya Yamanaka

Provided is a squamous cell carcinoma antigen derived peptide which is capable of binding to an HLA-A24 molecule and recognized by the cellular immune system, and a pharmaceutical composition comprising said peptide for the treatment or prevention of squamous cell carcinoma.

Squamous cell carcinoma antigen-derived peptide binding to HLA-A24 molecule

An object of the invention is to provide a peptide derived from a glioma-associated antigen being useful for the specific immunotherapy for glioma patients. The invention provides a KIF-derived peptide which is capable of binding to an HLA-A24 molecule and recognized by the cellular immune system, and a pharmaceutical composition comprising said peptide for the treatment or prevention of glioma.

HLA-A24-binding KIF-derived peptide

A cancer antigen peptide comprising an amino acid sequence shown in SEQ ID NO: 1 or 2, or a derivative thereof having the functionally equivalent property is provided. The provided cancer antigen peptide is a partial peptide derived from enhancer of zeste homolog 2, which is capable of binding to HLA-A24 antigen and is recognized by cytotoxic T lymphocytes. The cancer antigen peptide of the invention is useful for treatment and prevention of prostate cancer.

Growing community of inventors

Fukuoka, Japan

Mamoru Harada